Deal overview
| Target | TESARO INC |
|---|---|
| Bidder | GLAXOSMITHKLINE PLC |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | Dec 03, 2018 |
| Abstract | On 3 December 2018, the quoted UK-based healthcare company GlaxoSmithKline plc ("GSK"), announced a recommended offer for TESARO Inc ("TESARO"), a US-listed oncology-focused biopharmaceutical company. The offer of $75 per share represented an aggregate enterprise value of approximately $5.1 billion. The transaction was expected to complete in the first quarter of 2019 ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
